scholarly journals Low Dose Radiation Therapy for COVID-19 Pneumonia: A Pilot Study

2020 ◽  
Author(s):  
Daya Nand Sharma ◽  
Randeep Guleria ◽  
Naveet Wig ◽  
Anant Mohan ◽  
Goura Kisor Rath ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Clinical Efficacy ◽  
Low Dose ◽  
Controlled Trial ◽  
Pilot Trial ◽  
Early Warning Score ◽  
World Health ◽  
Radiation Toxicity ◽  
Low Dose Radiation ◽  
Dose Radiation

ABSTRACTBackgroundThe World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) as pandemic in March 2020. Currently there is no vaccine or specific effective treatment for COVID-19. The major cause of death in COVID-19 is severe pneumonia leading to respiratory failure. Radiation in low doses (<100 cGy) has been known for its anti-inflammatory effect and therefore, low dose radiation therapy (LDRT) to lungs can potentially mitigate the severity of pneumonia and reduce mortality. We conducted a pilot trial to study the feasibility and clinical efficacy of LDRT to lungs in the management of patients with COVID-19.MethodsFrom June to Aug 2020, we enrolled 10 patients with COVID-19 having moderate to severe risk disease [National Early Warning Score (NEWS) of ≥5]. Patients were treated as per the standard COVID-19 management guidelines along with LDRT to both lungs with a dose of 70cGy in single fraction. Response assessment was done based on the clinical parameters using the NEWS.ResultsAll patients completed the prescribed treatment. Nine patients had complete clinical recovery mostly within a period ranging from 3-7 days. One patient, who was a known hypertensive, showed clinical deterioration and died 24 days after LDRT. No patients showed the signs of acute radiation toxicity.ConclusionResults of our study (90% response rate) suggest the feasibility and clinical effectiveness of LDRT in COVID-19 patients having moderate to severe risk disease. This mandates a randomized controlled trial to establish the clinical efficacy of LDRT in COVID-19 pneumonia.

scholarly journals Low-dose radiation therapy for COVID-19 pneumonia: a pilot study

2021 ◽  
Vol 94 (1126) ◽  
pp. 20210187
Author(s):  
Daya Nand Sharma ◽  
Randeep Guleria ◽  
Naveet Wig ◽  
Anant Mohan ◽  
Goura Rath ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pilot Study ◽  
Randomized Controlled Trials ◽  
Clinical Efficacy ◽  
Low Dose ◽  
Early Warning Score ◽  
Controlled Trials ◽  
Low Dose Radiation ◽  
Randomized Controlled ◽  
Dose Radiation

Objectives: The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) as pandemic in March 2020. Currently there is no specific effective treatment for COVID-19. The major cause of death in COVID-19 is severe pneumonia leading to respiratory failure. Radiation in low doses (<100 cGy) has been known for its anti-inflammatory effect and therefore, low dose radiation therapy (LDRT) to lungs can potentially mitigate the severity of pneumonia and reduce mortality. We conducted a pilot trial to study the feasibility and clinical efficacy of LDRT to lungs in the management of patients with COVID-19. Methods: From June to Aug 2020, we enrolled 10 patients with COVID-19 having moderate to severe risk disease [National Early Warning Score (NEWS) of ≥5]. Patients were treated as per the standard COVID-19 management guidelines along with LDRT to both lungs with a dose of 70cGy in single fraction. Response assessment was done based on the clinical parameters using the NEWS. Results: All patients completed the prescribed treatment. Nine patients had complete clinical recovery mostly within a period ranging from 3 to 7 days. One patient, who was a known hypertensive, showed clinical deterioration and died 24 days after LDRT. No patients showed the signs of acute radiation toxicity. Conclusion: The results of our pilot study suggest that LDRT is feasible in COVID-19 patients having moderate to severe disease. Its clinical efficacy may be tested by conducting randomized controlled trials. Advances in knowledge: LDRT has shown promising results in COVID-19 pneumonia and should be researched further through randomized controlled trials.

scholarly journals Lack of beneficial effects of low-dose radiation therapy on hand osteoarthritis symptoms and inflammation: a randomised, blinded, sham-controlled trial

2018 ◽  
Vol 26 (10) ◽  
pp. 1283-1290 ◽  
Author(s):  
M.J.M. Minten ◽  
M.M. Leseman-Hoogenboom ◽  
M. Kloppenburg ◽  
M.C. Kortekaas ◽  
J.W. Leer ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Low Dose ◽  
Controlled Trial ◽  
Hand Osteoarthritis ◽  
Low Dose Radiation ◽  
Beneficial Effects ◽  
Dose Radiation

Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial

2018 ◽  
pp. annrheumdis-2018-214104 ◽  
Author(s):  
Elien A M Mahler ◽  
Michiel JM Minten ◽  
Mathilde M Leseman-Hoogenboom ◽  
Philip M P Poortmans ◽  
Jan Willem H Leer ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Knee Osteoarthritis ◽  
Low Dose ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Low Dose Radiation ◽  
Knee Oa ◽  
Sham Intervention ◽  
Double Blinded ◽  
Dose Radiation

ObjectivesLow-dose radiation therapy (LDRT) for benign disorders such as knee osteoarthritis (OA) is widely used in some parts of the world, despite absence of controlled studies. We evaluated the effect of LDRT on symptoms and inflammation in patients with knee OA.MethodsIn this randomised, double-blinded, sham-controlled clinical trial (RCT), we recruited patients with knee OA (clinical ACR criteria) in the Netherlands, aged ≥50 years, pain score ≥5/10 and non-responding to analgesics and exercise therapy. Patients were randomised 1:1 to receive LDRT (1 Gray per fraction) or sham intervention six times in 2 weeks, stratified by pain (<8 versus ≥8/10). Primary outcome was the proportion of OMERACT-OARSI responders, 3 months postintervention. Secondary outcomes included pain, function and inflammatory signs assessed by ultrasound, MRI and serum inflammatory markers.ResultsWe randomly assigned 55 patients: 27 (49%) to LDRT and 28 (51%) to sham. At 3 months postintervention, 12/27 patients (44%; 95%  CI 26% to 63%) in the LDRT vs 12/28 patients (43%; 95%  CI 25% to 61%) in the sham group responded; difference 2% (95% CI 25% to 28%), OR adjusted for the stratifying variable was 1.1 (95% CI 0.4 to 3.2). Also, for clinical and any of the inflammatory signs, no differences were observed.ConclusionsWe found no substantial beneficial effect on symptoms and inflammatory signs of LDRT in patients knee OA, compared with sham treatment. Therefore, based on this RCT and the absence of other high-quality evidence, we advise against the use of LDRT as treatment for knee OA.Trial registration numberNTR4574.

Plasma cell infiltration of the upper aerodigestive tract treated with radiation therapy

2001 ◽  
Vol 115 (11) ◽  
pp. 928-930 ◽  
Author(s):  
Gerald Fogarty ◽  
Hugh Turner ◽  
June Corry
Keyword(s):  
Radiation Therapy ◽  
Plasma Cell ◽  
Low Dose ◽  
Symptomatic Improvement ◽  
Upper Aerodigestive Tract ◽  
Low Dose Radiation ◽  
Base Of Tongue ◽  
First Case ◽  
Mucosal Lining ◽  
Dose Radiation

A case of chronic, fluctuating plasma cell gingivostomatitis that progressed despite chemotherapy and surgery is reported. This is the first case reported of treatment with radiation therapy, and one of the few cases reported where the infiltrate has reached the larynx. After receiving low dose radiation therapy, via a conformal technique encompassing the respiratory mucosal lining from the base of tongue to carina, there has been symptomatic improvement.

scholarly journals Low-Dose Radiation Therapy for COVID-19 Pneumonia: review

2020 ◽  
pp. 30-34
Author(s):  
N. Kolotilov
Keyword(s):  
Radiation Therapy ◽  
Low Dose ◽  
Ore Deposits ◽  
Molecular Targeting ◽  
Positive Experience ◽  
Low Dose Radiation ◽  
Coronavirus Infection ◽  
Positive Results ◽  
Dose Radiation ◽  
Radiolabeled Antibodies

The use of low-dose radiation therapy (LDRT) in patients with pneumonia from 1905 to 1943 provided positive results in 83.08 % of cases. Interest in LDRT is supported by researchers of radiation hormesis in the 21st century. Attention is drawn to the dynamics of coronavirus infection in the regions of Ukraine and the Kirovograd region with a minimum incidence. It is known that 95 % of uranium ore deposits in Ukraine are concentrated in the Kirovograd region. The positive experience of LDRT in Iran, India, USA, Spain for the treatment of patients with COVID-19 is described. LDRT (<100 cGy) is known to be anti-inflammatory, and therefore pulmonary LDRT has the potential to reduce the severity of pneumonia and reduce mortality. LDRT deserves a clinical study. A new direction in radiation therapy – Auger therapy based on radiolabeled antibodies – is planned to be used as a molecular targeting radiotherapy agent directly to the SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document